Patents by Inventor Peter Orth

Peter Orth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF PRODUCING A SINTER-HARDENED COMPONENT
    Publication number: 20110008639
    Abstract: The invention describes a method of producing a sinter-hardened component from a metallic powder containing chromium which is pre-alloyed in particular, comprising the steps of compacting the powder to form a green compact and then sintering the green compact in a reducing sintering atmosphere at a sintering temperature in excess of 1100° C. A gas containing carbon is added to the sintering atmosphere.
    Type: Application
    Filed: May 29, 2008
    Publication date: January 13, 2011
    Applicant: Miba Sinter Austria GmbH
    Inventors: Peter Orth, Gerold Stetina
  • Engineered Anti-IL-23 Antibodies
    Publication number: 20110002942
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: September 14, 2010
    Publication date: January 6, 2011
    Applicant: Schering Corporation
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof
    Patent number: 7824897
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: November 2, 2010
    Assignee: Schering Corp.
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
  • ENGINEERED ANTI-IL-23P19 ANTIBODIES
    Publication number: 20100272731
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 21, 2008
    Publication date: October 28, 2010
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Engineered anti-IL-23 antibodies
    Patent number: 7807160
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: October 5, 2010
    Assignee: Schering Corporation
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF
    Publication number: 20100184111
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Application
    Filed: February 9, 2010
    Publication date: July 22, 2010
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey Strickland
  • COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20100145048
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Application
    Filed: October 20, 2009
    Publication date: June 10, 2010
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert D. Mazzola, Tin-Yau Chan, Henry A. Vaccaro, Brian McKittrick, Joseph A. Kozlowski, Brian J. Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline C. Ting, Kristin E. Rosner, Gerald W. Shipps, JR., M. Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Dansu Li, Vinay M. Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao
  • ENGINEERED ANTI-IL-23P19 ANTIBODIES
    Publication number: 20100111966
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 21, 2008
    Publication date: May 6, 2010
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof
    Patent number: 7700753
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7687527
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 30, 2010
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Umar Faruk Mansoor, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7683085
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 23, 2010
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7652020
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: January 26, 2010
    Assignee: Schering Corporation
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert D. Mazzola, Tin-Yau Chan, Henry A. Vaccaro, Brian McKittrick, Joseph A. Kozlowski, Brian J. Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline C. Ting, Kristin E. Rosner, Gerald W. Shipps, Jr., M. Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Dansu Li, Vinay M. Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao
  • MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF
    Publication number: 20090221016
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Application
    Filed: April 8, 2009
    Publication date: September 3, 2009
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey Strickland
  • COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20090170875
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: July 2, 2009
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K.C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Umar Faruk Mansoor, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li
  • ENGINEERED ANTI-IL-23 ANTIBODIES
    Publication number: 20090156788
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 13, 2009
    Publication date: June 18, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20090137586
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: May 28, 2009
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K.C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Razia Rizvi, Aneta M. Micula, Robert Feltz
  • Methods for identifying modified tumor necrosis factor-alpha converting enzyme inhibitors
    Patent number: 7529628
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: May 5, 2009
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
  • COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20090111803
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF—or combinations thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: April 30, 2009
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K.C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankat
  • Ion channel modulating activity method
    Patent number: 7507545
    Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: March 24, 2009
    Assignee: Cardiome Pharma Corp.
    Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter Orth
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7504424
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: March 17, 2009
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Umar Faruk Mansoor, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li